⚠️ Current Drug Shortages

Teva Pharmaceuticals has told the FDA it is discontinuing its fluocinonide ointment products — a company stopping its own product, not a nationwide shortage. 3 other companies still list the same medicine without a shortage report.

Reporting: Teva Pharmaceuticals USA, Inc.

Merck Sharp & Dohme is stopping its ivermectin 3 mg tablets, with the change taking effect October 31, 2026. Other manufacturers — including Edenbridge Pharmaceuticals, A-S Medication Solutions, and NuCare Pharmaceuticals — still list ivermectin 3 mg tablets, including the brand Stromectol, as available sources.

Reporting: Merck Sharp & Dohme LLC

Janssen Pharmaceuticals is stopping Xarelto (rivaroxaban) for suspension, and this change may be permanent. The 155 mg suspension is still listed by Ascend Laboratories as a source not reporting a shortage.

Reporting: Janssen Pharmaceuticals

Viatris is permanently stopping its rivastigmine extended-release film patch. The same medicine — including Exelon (rivastigmine) patches — is still listed as available from other manufacturers that have not reported a shortage.

Reporting: Mylan Pharmaceuticals Inc., a Viatris Company

Fresenius Kabi is permanently stopping production of Melphalan Hydrochloride Injection. The same medicine is still listed by other makers, including Heritage Pharmaceuticals, Sagent, Dr. Reddy's, and BPI Labs.

Reporting: Fresenius Kabi USA, LLC

Par Health is permanently stopping its micafungin sodium injection (20 mg/mL and 10 mg/mL vials) due to a business decision. Other makers — including Hikma, Sagent, Hisun, and Fresenius Kabi — still list micafungin injection in 50 mg and 100 mg strengths.

Reporting: Par Health, USA LLC

Fresenius Medical Care is permanently stopping production of DELFLEX (dextrose monohydrate, sodium chloride, sodium lactate, calcium chloride, and magnesium chloride solution). No other manufacturers are currently listed as a source for this medicine.

Reporting: Fresenius Medical Care North America

Merck Sharp & Dohme is stopping RECARBRIO (imipenem/cilastatin/relebactam) injection, and the change is expected to be permanent. No other manufacturer makes this medicine, so all strengths will be unavailable once the discontinuation takes effect.

Reporting: Merck Sharp & Dohme LLC

Amgen is permanently stopping its glycerol phenylbutyrate oral liquid (1.1 g/mL), and this change may be permanent. Other makers — including Teva Pharmaceuticals, Camber Pharmaceuticals, Par Health USA, and Aurobindo Pharma — still list the same medicine at the same strength.

Reporting: Amgen Inc.

Eli Lilly is stopping Rezvoglar (insulin glargine-aglr) injection, with distribution expected to end in June 2027. The 100 units/mL KwikPen is still listed as available from at least one other supplier.

Reporting: Eli Lilly and Co.

Eli Lilly is stopping Humalog Mix 75/25 (insulin lispro protamine and insulin lispro) permanently. No other manufacturer currently lists this medicine as available.

Reporting: Eli Lilly and Co.

Pfizer is permanently stopping production of Provera (medroxyprogesterone acetate) tablets, with withdrawal from sale expected by late 2026. Other manufacturers still list this medicine in 2.5 mg, 5 mg, and 10 mg strengths.

Reporting: Pfizer Inc.

Teva is permanently stopping its metoprolol succinate extended-release tablets — all strengths (25 mg, 50 mg, 100 mg, and 200 mg) are affected. Other manufacturers, including Major Pharmaceuticals and Camber Pharmaceuticals, still list the 25 mg, 50 mg, and 100 mg strengths as available.

Reporting: Teva Pharmaceuticals USA, Inc.

Ipsen is permanently stopping production of Sohonos (palovarotene) capsules. No other manufacturer makes this medicine, so no listed source exists for any strength.

Reporting: Ipsen Biopharmaceuticals, Inc.

Fresenius Kabi is stopping production of this potassium chloride/sodium chloride/calcium chloride/magnesium chloride injection solution, and the change may be permanent. Plegisol (potassium chloride, sodium chloride, calcium chloride injection solution) from Hospira is listed as an available option from a manufacturer not reporting a shortage.

Reporting: Fresenius Kabi USA, LLC

Nipent (pentostatin) injection is currently unavailable due to manufacturing delays at Pfizer, with no supply expected until mid-2027 at the earliest. No other manufacturers of this medicine are listed as an alternative source right now.

Why: Other

Reporting: Hospira, Inc., a Pfizer Company

Mylan is permanently stopping its mesalamine extended-release capsules, and Takeda plans to stop supplying its version by end of 2027. Other makers — including Teva and Upsher-Smith — have not reported a shortage and still list mesalamine extended-release capsules as available.

Reporting: Mylan Pharmaceuticals Inc., a Viatris Company, Takeda Pharmaceuticals USA Inc.

Pfizer is stopping production of Norpace CR (disopyramide phosphate) extended-release capsules, and this change may be permanent. Immediate-release disopyramide capsules in 100 mg and 150 mg are still listed by other manufacturers who have not reported a shortage.

Reporting: Pfizer Inc.

Fresenius Kabi is permanently stopping production of fulvestrant injection (250 mg/5 mL). The same medicine — including Faslodex (fulvestrant) — is still listed as available from other manufacturers not reporting a shortage.

Reporting: Fresenius Kabi USA, LLC

Teva is permanently stopping its diclofenac sodium delayed-release tablets. Other makers — including Rising Pharma, AvKARE, Edenbridge, and PD-Rx — still list this medicine in 25 mg, 50 mg, and 75 mg strengths, so supply may be available from other sources.

Reporting: Teva Pharmaceuticals USA, Inc.

Salix Pharmaceuticals is permanently stopping its version of this bowel-prep solution. The same medicine is still listed by other makers, including as MoviPrep and Plenvu.

Reporting: Salix Pharmaceuticals, a division of Bausch Health US, LLC

Sanofi-Aventis is permanently discontinuing its glyburide tablets. Other manufacturers, including Teva and Heritage Pharmaceuticals, still list glyburide in all three strengths (1.25 mg, 2.5 mg, and 5 mg) as available.

Reporting: Sanofi-Aventis U.S. LLC

Vantive US Healthcare LLC is stopping production of this intraperitoneal dialysis solution, and the change may be permanent. Some Dianeal formulations from Vantive are still listed as available, including Dianeal Low Calcium and Dianeal PD-2 with Dextrose in several strengths.

Reporting: Vantive US Healthcare LLC

Teva is permanently stopping its doxycycline hyclate delayed-release tablet. Delayed-release versions at 75 mg and 100 mg are still listed by other manufacturers not reporting a shortage.

Reporting: Teva Pharmaceuticals USA, Inc.

Fresenius Kabi is permanently stopping production of glycopyrrolate injection. Other makers — including Hikma, American Regent, Sandoz, and Accord — still list glycopyrrolate injection in multiple strengths without reporting a shortage.

Reporting: Fresenius Kabi USA, LLC

GlaxoSmithKline is stopping its Advair HFA (fluticasone/salmeterol) inhaler, with distribution ending around December 31, 2026. Other manufacturers still list Advair HFA and fluticasone/salmeterol HFA inhalers as available.

Reporting: GlaxoSmithKline

Kaletra (lopinavir and ritonavir) oral solution is being permanently discontinued by AbbVie. No other makers list this medicine as available right now.

Reporting: AbbVie Inc.

AbbVie is stopping production of Kaletra (lopinavir/ritonavir) tablets, and this change may be permanent. Generic versions of the same medicine are still listed by other manufacturers.

Reporting: AbbVie Inc.

Norvir (ritonavir) oral powder is being discontinued by AbbVie, and this change may be permanent. No other maker lists this powder form as available right now.

Reporting: AbbVie Inc.

AbbVie is stopping production of Norvir (ritonavir) tablets, and this change may be permanent. The 100 mg tablet is still listed by other manufacturers that have not reported a shortage.

Reporting: AbbVie Inc.

Padagis is permanently stopping production of aspirin suppositories (300 mg), and no other manufacturer currently lists this product. This strength has no known available source at this time.

Reporting: Padagis US LLC

Padagis is permanently stopping production of Belladonna and Opium suppositories. No other manufacturer is listed as a source for any strength of this medicine right now.

Reporting: Padagis US LLC

Teva is permanently stopping Treanda (bendamustine hydrochloride injection). Other makers, including Baxter Healthcare, Accord Healthcare, Azurity Pharmaceuticals, and Eagle Pharmaceuticals, still list bendamustine hydrochloride injection in multiple strengths and forms.

Reporting: Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.)

Padagis is permanently stopping production of hydrocortisone acetate suppositories. Other manufacturers — including makers of Anucort-HC (hydrocortisone acetate) — still list both the 25 mg and 30 mg suppositories as available.

Reporting: Padagis US LLC

Padagis is stopping production of hydromorphone hydrochloride suppositories, and this change may be permanent. The 3 mg suppository is still listed by Bryant Ranch Prepack, which has not reported a shortage.

Reporting: Padagis US LLC

Padagis is permanently stopping production of morphine sulfate suppositories, and no other manufacturer is currently listed as a source for any strength. This medicine is not available from any reported maker right now.

Reporting: Padagis US LLC

Padagis is stopping production of Podophyllum Resin Topical Tincture, and this change may be permanent. Podocon-25 (podophyllum resin) 1 mg/4 mL tincture is still listed as available from Bryant Ranch Prepack.

Reporting: Padagis US LLC

Fresenius Kabi is stopping production of Succinylcholine Chloride Injection 20 mg/mL, and this change may be permanent. The same medicine at the same strength is still listed by other manufacturers, including Quelicin (succinylcholine chloride) from Hospira.

Reporting: Fresenius Kabi USA, LLC

Pfizer (Hospira) is permanently stopping its tobramycin sulfate injection. The same medicine at both 40 mg/mL and 10 mg/mL strengths is still listed as available from other manufacturers, including Baxter Healthcare, Fresenius Kabi, and Mylan Institutional.

Reporting: Hospira, Inc., a Pfizer Company

Mylan is permanently stopping its travoprost ophthalmic solution, affecting both the 2.5 mL and 5 mL sizes. Other makers — including Novartis, Sagent, Micro Labs, and Golden State Medical Supply — still list travoprost eye drops (including Travatan Z), so supply may be available from other sources.

Reporting: Mylan Pharmaceuticals Inc., a Viatris Company

Jiangsu Hengrui is permanently stopping production of desflurane liquid for inhalation. Suprane (desflurane) 240 mL is still listed as available from Baxter Healthcare.

Reporting: Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)

Jiangsu Hengrui is permanently stopping its daptomycin injection. Other makers — including Hikma, Hospira, and Accord — still list daptomycin in 350 mg and 500 mg strengths and have not reported a shortage.

Reporting: Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)

Jiangsu Hengrui is discontinuing its gadobutrol injection single-dose vials, and this change may be permanent. The same medicine at 604.72 mg/mL — including Gadavist (gadobutrol) — is still listed by other manufacturers not reporting a shortage.

Reporting: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Gilead Sciences is stopping Emtriva (emtricitabine) capsules, and this change may be permanent. Supply from Gilead is expected to last until March 2027; a 200 mg capsule is also listed by Cipla USA as a source not currently reporting a shortage.

Reporting: Gilead Sciences, Inc.

Gilead Sciences is stopping its emtricitabine oral solution (10 mg/mL), and this change is expected to be permanent. No other manufacturers of this liquid form are currently listed, so supply will not be available after March 2027.

Reporting: Gilead Sciences, Inc.

Amneal Pharmaceuticals is permanently stopping its generic donepezil/memantine extended-release capsules. Namzaric (donepezil/memantine) capsules in multiple strengths are still listed as available from other manufacturers not reporting a shortage.

Reporting: Amneal Pharmaceuticals

Pfizer is stopping Lorbrena (lorlatinib) 25 mg tablets in the 120-count bottle, and this change may be permanent. The 30-count bottle of the same strength will continue to be made by Pfizer, with current supply expected to last through June 30, 2026.

Reporting: Pfizer Inc.

IFEX (ifosfamide) injection is in short supply, with most brand products still available but several generic versions unavailable or limited. The 50 mg/mL strength has no listed source right now; other strengths remain available from some makers, with Hikma expecting more supply around September 2026.

Why: Demand increase for the drug; Requirements related to complying with good manufacturing practices

Reporting: Baxter Healthcare, Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA, Inc., SteriMax, Inc.

Pfizer is permanently stopping production of Vizimpro (dacomitinib) tablets. No other manufacturer makes this medicine, so all strengths — 15 mg, 30 mg, and 45 mg — are losing their only listed source.

Reporting: Pfizer Inc.

Sanofi-Aventis is permanently stopping production of Arava (leflunomide) tablets. Generic leflunomide 10 mg and 20 mg tablets are still listed by other manufacturers; the 100 mg strength has no listed source from any maker right now.

Reporting: Sanofi-Aventis U.S. LLC

Novo Nordisk is stopping all Rybelsus (semaglutide) tablets, and this change may be permanent. Novo Nordisk states Rybelsus will be replaced by Ozempic (semaglutide) tablets, and no other manufacturer currently lists this medicine as available.

Reporting: Novo Nordisk, Inc.

Accord Healthcare is discontinuing the 10-pack of Dehydrated Alcohol Injection, and the change may be permanent. Accord is switching to a 5-pack version (NDC 16729-710-53), and other makers still list this medicine as available.

Reporting: Accord Healthcare Inc.

Fresenius Kabi is permanently stopping production of its gadoterate meglumine injection. The 376.9 mg/mL strength is still listed as available from other manufacturers, including as Dotarem and Clariscan (gadoterate meglumine).

Reporting: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Genentech is permanently discontinuing the alteplase injection 100 mg vial. The Activase kit, which also contains alteplase, is still listed by Genentech as available.

Reporting: Genentech, Inc

Mylan Institutional is permanently stopping its iron sucrose injection 50 mg/2.5 mL vial. Other strengths and brands — including Venofer (iron sucrose) and generic versions from several makers — are still listed as available.

Reporting: Mylan Institutional, a Viatris Company

Padagis is stopping production of Actidose and Actidose Aqua (activated charcoal oral suspension), and the change may be permanent. A similar product, Insta-Char Aqueous activated charcoal suspension, is still listed by VistaPharm as a possible alternative.

Reporting: Padagis US LLC

Journey Medical Corporation is permanently stopping sulconazole nitrate 1% solution (sold under their label and for JG Pharma). No other manufacturer of this solution is currently listed as having supply available.

Reporting: Journey Medical Corporation

Fresenius Kabi is permanently stopping its icatibant acetate injection, and no supply from them remains. Other makers — including Takeda, Hikma, Teva, and Eugia — still list icatibant acetate injection, including Firazyr (icatibant acetate), so the medicine has sources available.

Reporting: Fresenius Kabi USA, LLC

Pfizer (Hospira) is permanently stopping production of cisatracurium besylate injection, with supply expected to run out by late 2026. Other makers — including Hikma, Sandoz, Camber, and Eugia — still list both the 2 mg/mL and 10 mg/mL strengths.

Reporting: Hospira, Inc., a Pfizer Company

Par Health is permanently stopping its lamotrigine extended-release tablets. Other strengths of lamotrigine extended-release are still listed by manufacturers that have not reported a shortage, though only orally disintegrating tablets (not extended-release) appear in those listings.

Reporting: Par Health, Inc.

Neurocrine Biosciences is stopping the 25 mg capsule of Crenessity (crinecerfont), and this change may be permanent. The 50 mg and 100 mg capsule strengths are not part of this discontinuation, but no other manufacturer lists the 25 mg strength as available.

Reporting: Neurocrine Biosciences, Inc.

Janssen is stopping production of Intelence (etravirine) tablets, and this change may be permanent. Other makers not reporting a shortage still list etravirine tablets in 100 mg and 200 mg strengths.

Reporting: Janssen Research and Development

Pfizer is permanently stopping production of Ibrance (palbociclib) capsules. Pfizer will continue making Ibrance tablets in both the 75 mg and 100 mg strengths as replacements for the capsules.

Reporting: Pfizer Inc.

Viatris is stopping its manufacture of ketorolac tromethamine 10 mg tablets, and the change may be permanent. Other makers — including Teva, Major Pharmaceuticals, Ajanta Pharma, and Camber — still list the same 10 mg tablet as available.

Reporting: Mylan Pharmaceuticals Inc., a Viatris Company

Isocarboxazid (Marplan) 10 mg tablets are currently in shortage, though the one manufacturer on record, Lifsa Drugs, still lists some supply available. No other makers of this medicine are on file, so availability may be limited.

Why: Other

Reporting: Lifsa Drugs LLC

Teva is permanently stopping production of tiagabine hydrochloride tablets. Other makers — including Sun Pharmaceutical, Cephalon, and Novadoz — have not reported a shortage and still list the 2 mg and 4 mg strengths.

Reporting: Teva Pharmaceuticals USA, Inc.

AbbVie is permanently stopping production of its nitroglycerin 0.4% ointment. Other makers — including Cosette Pharmaceuticals, Encube Ethicals, Trupharma, and Bryant Ranch Prepack — still list nitroglycerin ointment as available.

Reporting: AbbVie Inc.

Amneal Pharmaceuticals is stopping production of nitrofurantoin oral suspension (25 mg/5 mL), and this change may be permanent. Other makers, including Rising Pharma, Lupin, and Aurobindo, still list nitrofurantoin oral suspension at both 25 mg/5 mL and 50 mg/5 mL strengths.

Reporting: Amneal Pharmaceuticals

Pfizer is permanently stopping production of Zithromax (azithromycin) tablets. Other makers, including Sandoz and Lannett, still list the 250 mg and 500 mg tablets as available, so the medicine can still be found from other sources.

Reporting: Pfizer Inc.

Merck is stopping aprepitant oral powder for suspension (125 mg), and this change may be permanent. No other manufacturers of this form are listed as having supply available right now.

Reporting: Merck Sharp & Dohme LLC

Fresenius Kabi is permanently stopping production of its fosaprepitant dimeglumine injection. The 150 mg/5 mL strength is still listed by other manufacturers, including as Emend (fosaprepitant dimeglumine).

Reporting: Fresenius Kabi USA, LLC

Gilead Sciences is stopping Zydelig (idelalisib) tablets, and this change may be permanent. No other makers list either the 100 mg or 150 mg strength, so there is currently no listed source for this medicine.

Reporting: Gilead Sciences, Inc.

Strides Pharma is permanently stopping its ursodiol 300 mg capsules. Other manufacturers — including Lannett, Actavis, Major Pharmaceuticals, and KVK-Tech — still list ursodiol 300 mg capsules as available.

Reporting: Strides Pharma Inc.

Apotex is permanently stopping its icosapent ethyl capsules. The 1 g strength is still listed as available from other makers, including Hikma, Teva, Northstar Rx, and Camber Pharmaceuticals.

Reporting: Apotex Corp.

Furosemide oral solution is in short supply because of a shortage of an inactive ingredient. Hikma still lists both the 40 mg/5 mL and 10 mg/mL strengths but is filling orders on allocation only; Precision Dose also lists furosemide oral solution from outside the shortage.

Why: Shortage of an inactive ingredient component

Reporting: Hikma Pharmaceuticals USA, Inc.

Amneal Pharmaceuticals is permanently stopping production of dapsone gel 7.5%. Other brands and generics of dapsone gel, including Aczone (dapsone) gel, are still listed by other manufacturers.

Reporting: Amneal Pharmaceuticals

AbbVie is permanently stopping production of Crinone (progesterone vaginal gel) 4%. No other makers of this gel are currently listed as having supply available.

Reporting: AbbVie Inc.

Epizyme is permanently stopping production of Tazemetostat Hydrobromide tablets (the cancer medicine sold as Tazverik), and no supply remains. No other manufacturer of this medicine has been found in our records.

Reporting: Epizyme, Inc. (An Ipsen Company)

Torrent Pharmaceuticals is permanently stopping its generic nebivolol hydrochloride tablets in all strengths. Bystolic (nebivolol hydrochloride) tablets in all four strengths are still listed by other manufacturers not reporting a shortage.

Reporting: Torrent Pharmaceuticals Limited

Amgen is permanently stopping its version of ivabradine hydrochloride tablets. Other manufacturers — including Camber Pharmaceuticals, Ingenus Pharmaceuticals, and Golden State Medical Supply — still list both the 5 mg and 7.5 mg strengths as available.

Reporting: Amgen Inc.

Amgen is permanently stopping production of ivabradine oral solution (5 mg/5 mL). No other manufacturer of this form is currently listed as having supply available.

Reporting: Amgen Inc.

AbbVie is permanently stopping production of Vuity (pilocarpine hydrochloride) eye drops. Other manufacturers not reporting a shortage still list pilocarpine hydrochloride eye drops in multiple strengths as available.

Reporting: AbbVie Inc.

XGen Pharmaceuticals is permanently stopping its pentamidine isethionate injection. Other manufacturers — including Fresenius Kabi and Seton Pharmaceuticals — still list this medicine, including Pentam 300 (pentamidine isethionate) 300 mg, so supply may be available from other sources.

Reporting: XGen Pharmaceuticals DJB, Inc.

Rozerem (ramelteon) tablets are being discontinued by Takeda Pharmaceuticals. The 8 mg strength is still listed by other makers, including Actavis Pharma, Upsher-Smith Laboratories, Major Pharmaceuticals, and AvKARE.

Reporting: Takeda Pharmaceuticals USA Inc.

Fresenius Kabi is permanently stopping its plerixafor injection, a medicine used to help collect stem cells for transplant. Other makers — including the brand Mozobil (plerixafor) from Sanofi-Aventis — have not reported a shortage and still list supply.

Reporting: Fresenius Kabi USA, LLC

DELFLEX® w/Dextrose (peritoneal dialysis solution) is being discontinued by Fresenius Medical Care. The product will be replaced with items under a new labeling code, and no other manufacturers currently list this solution as available.

Reporting: Fresenius Medical Care North America

Amneal Pharmaceuticals is stopping production of Clindamycin Palmitate Hydrochloride Injection (75 mg/5 mL), and this change may be permanent. No other manufacturers are currently listed as a source for this medicine.

Reporting: Amneal Pharmaceuticals

Janssen Pharmaceuticals is permanently stopping its itraconazole 100 mg capsules. Other makers — including Torrent Pharmaceuticals, Rising Pharma, NorthStar Rx, and AvPAK — have not reported a shortage and still list this medicine as available.

Reporting: Janssen Pharmaceuticals

Lincocin (lincomycin hydrochloride) injection is being discontinued by both Pfizer and XGen Pharmaceuticals, and this change may be permanent. Lincocin is still listed as available from other manufacturers not reporting a shortage.

Reporting: Pfizer Inc., XGen Pharmaceuticals DJB, Inc.

Pfizer is permanently stopping its Cleocin Hydrochloride (clindamycin hydrochloride) capsules. The same capsules in 75 mg, 150 mg, and 300 mg strengths are still listed by other manufacturers that have not reported a shortage.

Reporting: Pfizer Inc.

Both Fresenius Kabi and Ingenus Pharmaceuticals are permanently stopping production of arsenic trioxide injection. Other makers — including Sandoz, Nexus Pharmaceuticals, Heritage Pharma, and Sagent Pharmaceuticals — still list arsenic trioxide injection in both 1 mg/mL and 2 mg/mL strengths as available.

Reporting: Fresenius Kabi USA, LLC, Ingenus Pharmaceuticals LLC

Ingenus Pharmaceuticals is permanently stopping its irinotecan hydrochloride injection, a chemotherapy medicine used to treat certain cancers. Other manufacturers — including the makers of Camptosar (irinotecan hydrochloride) — have not reported a shortage, so supply may still be available from other sources.

Reporting: Ingenus Pharmaceuticals LLC

BluePoint Laboratories is permanently stopping its decitabine injection. The 50 mg form is still listed as available from other manufacturers, including Hikma, Accord Healthcare, Sagent, and Camber Pharmaceuticals.

Reporting: Ingenus Pharmaceuticals LLC

Ingenus Pharmaceuticals is permanently discontinuing its docetaxel injection 10 mg/mL. Other manufacturers — including Hikma, Hospira, Sanofi-Aventis, and Accord Healthcare — still list docetaxel injection in other strengths and forms.

Reporting: Ingenus Pharmaceuticals LLC

Teva is permanently stopping its allopurinol tablets. Both the 100 mg and 300 mg strengths are still listed by other makers, including Mylan, Par, Major Pharmaceuticals, and Rising Pharma.

Reporting: Teva Pharmaceuticals USA, Inc.

Fresenius Kabi is permanently stopping its cefepime hydrochloride injection, and this change may be lasting. The same medicine in both 1 g and 2 g strengths is still listed as available from other manufacturers, including Hikma, Hospira, Sagent, and WG Critical Care.

Reporting: Fresenius Kabi USA, LLC

Diuril (chlorothiazide) oral suspension is being permanently discontinued by its manufacturer. No other maker of this suspension is currently listed, so there is no known alternative source for this form of the medicine right now.

Reporting: Salix Pharmaceuticals, a division of Bausch Health US, LLC

Pfizer is permanently stopping production of gemfibrozil 600 mg tablets. The same medicine — including Lopid (gemfibrozil) 600 mg — is still listed as available from other manufacturers not reporting a shortage.

Reporting: Pfizer Inc.

Sun Pharmaceutical is permanently stopping production of pindolol tablets, with the last batches expiring by early 2027. Both the 5 mg and 10 mg strengths are still listed by other manufacturers, including Marlex Pharmaceuticals, ANI Pharmaceuticals, Westminster Pharmaceuticals, and Bryant Ranch Prepack.

Reporting: Sun Pharmaceutical Industries, Inc.

AbbVie is permanently stopping production of Podofilox 0.5% topical gel. The same medicine in gel form is still listed as available from Padagis.

Reporting: AbbVie Inc.

Fresenius Kabi is permanently stopping production of benztropine mesylate injection. The 1 mg/mL strength is still listed as available from other manufacturers not reporting a shortage.

Reporting: Fresenius Kabi USA, LLC

Sandoz is stopping all of its Lescol XL (fluvastatin) extended-release tablets, and this change may be permanent. The 80 mg generic version is still listed by other makers who have not reported a shortage.

Reporting: Sandoz Inc.

Pfizer is permanently stopping production of Zithromax IV (azithromycin injection). The same medicine at the 500 mg strength is still listed as available from other manufacturers, including Sagent Pharmaceuticals, Eugia US LLC, Sun Pharmaceutical Industries, and Fresenius Kabi USA.

Reporting: Pfizer Inc.

Selzentry (maraviroc) oral solution is being discontinued — ViiV Healthcare plans to stop distributing it around August 1, 2026. No other manufacturers of this oral solution appear in our records.

Reporting: ViiV Healthcare Company

Fresenius Kabi is permanently stopping its piperacillin-tazobactam injection 2.25 g vials. Other manufacturers — including B. Braun Medical, Sagent Pharmaceuticals, WG Critical Care, and Eugia — still list piperacillin-tazobactam in multiple strengths and forms.

Reporting: Fresenius Kabi USA, LLC

Glaukos Corporation is stopping production of the Photrexa Cross-linking Kit (riboflavin 5-phosphate ophthalmic solution), and this change may be permanent. No other manufacturer of this medicine has been identified in FDA shortage records.

Reporting: Glaukos Corporation

Sandoz is stopping its version of Hyrimoz (adalimumab-adaz) injection, and this change may be permanent. Sandoz notes an equivalent Sandoz format is available; Hyrimoz is also still listed by Cordavis in multiple strengths.

Reporting: Sandoz Inc.

Sandoz and Fresenius Kabi are permanently stopping production of their caspofungin acetate injection. The same medicine — including Cancidas (caspofungin acetate) — is still listed as available from other manufacturers not reporting a shortage.

Reporting: Fresenius Kabi USA, LLC, Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)

Viatris (through its Mylan unit) is permanently stopping its doxycycline hyclate tablets. The 100 mg tablet is still listed as available from other manufacturers not reporting a shortage.

Reporting: Mylan Pharmaceuticals Inc., a Viatris Company

Viatris (formerly Mylan) is permanently stopping its doxylamine-pyridoxine delayed-release tablets. The same 10 mg strength is still listed by other makers, including the brand Diclegis (doxylamine-pyridoxine) from Duchesnay USA.

Reporting: Mylan Pharmaceuticals Inc., a Viatris Company

Fresenius Kabi is permanently stopping its neostigmine methylsulfate injection. Other manufacturers have not reported a shortage and still list this medicine as available.

Reporting: Fresenius Kabi USA, LLC

Fresenius Kabi is permanently stopping production of haloperidol decanoate injection 50 mg/mL. Other makers — including Hikma, Patriot Pharmaceuticals, Sagent, and Janssen — still list both the 50 mg/mL and 100 mg/mL strengths as available.

Reporting: Fresenius Kabi USA, LLC

Merck Sharp & Dohme is discontinuing Primaxin (imipenem and cilastatin) injection, and the change is expected to be permanent around November 30, 2026. Other makers — WG Critical Care and Fresenius Kabi — have not reported a shortage and still list this medicine in 250 mg and 500 mg strengths.

Reporting: Merck Sharp & Dohme Corp.

Pfizer (Hospira) is permanently stopping its diltiazem hydrochloride injection. The 5 mg/mL injectable form of this medicine is still listed as available from other manufacturers.

Reporting: Hospira, Inc., a Pfizer Company

Teva is permanently stopping its hydroxychloroquine sulfate tablets. The 200 mg tablet is still listed as available from other manufacturers, including Major Pharmaceuticals, Rising Pharma, Northstar Rx, and Accord Healthcare.

Reporting: Teva Pharmaceuticals USA, Inc.

Amneal Pharmaceuticals is stopping its sodium oxybate solution, and the change may be permanent. The same medicine is still listed by other makers, including Xyrem (sodium oxybate) solution from Jazz Pharmaceuticals.

Reporting: Amneal Pharmaceuticals

Eli Lilly is permanently discontinuing Omvoh (mirikizumab-mrkz) 100 mg/1 mL injection, with distribution ending April 2026. The 200 mg/2 mL presentation of Omvoh will remain available as a replacement.

Reporting: Eli Lilly and Co.

Upsher-Smith is permanently stopping its morphine sulfate tablets (15 mg and 30 mg). Other makers — including Hikma, SpecGx, and Major Pharmaceuticals — still list both strengths as available.

Reporting: Upsher-Smith Laboratories, LLC

Takeda Pharmaceuticals is permanently discontinuing its carbamazepine extended-release capsules. Other manufacturers — including Major Pharmaceuticals, AvPAK, Apotex, and ANI Pharmaceuticals — still list the 100 mg, 200 mg, and 300 mg strengths as available.

Reporting: Takeda Pharmaceuticals USA Inc.

Sanofi-Aventis is permanently stopping Hectorol (doxercalciferol) injection. Generic doxercalciferol injection is still listed by other manufacturers who have not reported a shortage.

Reporting: Sanofi-Aventis U.S. LLC

Pfizer is stopping production of spironolactone tablets, and this change may be permanent. The same medicine is still listed by other makers not reporting a shortage, including 25 mg, 50 mg, and 100 mg strengths.

Reporting: Pfizer Inc.

Sandoz is stopping its private-label ampicillin sodium injection, and this change may be permanent. Other makers — including Sagent Pharmaceuticals and WG Critical Care — still list ampicillin sodium injection in multiple strengths, so the medicine remains available from other sources.

Reporting: Sandoz Inc.

Teva is permanently stopping its calcitriol capsules — this is a business decision, not a temporary shortage. Other makers still list calcitriol capsules in both 0.25 mcg and 0.5 mcg strengths, so the medicine may still be available through other sources.

Reporting: Teva Pharmaceuticals USA, Inc.

Pfizer (Hospira) is permanently stopping its Sodium Chloride 0.9% Injection in ADD-Vantage flexible containers (50 mL, 100 mL, and 250 mL sizes). Other makers — including B. Braun, Baxter, Nephron, and ICU Medical — still list sodium chloride 0.9% injection as available.

Reporting: Hospira, Inc., a Pfizer Company

Merck is stopping production of posaconazole injection (18 mg/mL), and this change may be permanent. The same medicine is still listed as available from other makers not reporting a shortage.

Reporting: Merck Sharp & Dohme Corp.

Advanz Pharma is stopping production of nilutamide 150 mg tablets, and this change is permanent. The same strength is still listed as available from ANI Pharmaceuticals.

Reporting: Advanz Pharma (US) Corp.

Advanz Pharma is permanently stopping production of Dibenzyline (phenoxybenzamine hydrochloride) capsules. The 10 mg capsule is still listed by other manufacturers not reporting a shortage.

Reporting: Advanz Pharma (US) Corp.

Teva is permanently stopping its potassium chloride extended-release tablets. Other makers have not reported a shortage, and Klor-Con (potassium chloride) extended-release tablets in several strengths remain listed as available from them.

Reporting: Teva Pharmaceuticals USA, Inc.

Pfizer is permanently stopping production of Verapamil Hydrochloride Injection 2.5 mg/mL. Other makers — including Hospira, Sagent, and Micro Labs — still list this same strength as available.

Reporting: Pfizer Inc.

Teva is permanently stopping its anagrelide hydrochloride capsules — a business decision that will not be reversed. Other makers, including those that sell Agrylin (anagrelide) and generic versions in both 0.5 mg and 1 mg capsules, have not reported a shortage.

Reporting: Teva Pharmaceuticals USA, Inc.

Teva is permanently stopping its hydrochlorothiazide 12.5 mg capsules. Other makers, including Actavis Pharma and Unichem Pharmaceuticals, still list this same strength and form as available.

Reporting: Teva Pharmaceuticals USA, Inc.

Mylan is permanently stopping its valsartan tablets — a business decision, not a temporary shortage. Other makers, including the brand Diovan (valsartan), still list the same strengths as available sources.

Reporting: Mylan Pharmaceuticals Inc., a Viatris Company

Organon is permanently stopping production of its chewable montelukast sodium 4 mg tablets. Other makers not reporting a shortage still list chewable montelukast sodium 4 mg tablets as available.

Reporting: Organon

Pfizer (Hospira) is permanently stopping production of its ceftazidime injection. Other makers — including Sagent Pharmaceuticals and WG Critical Care — still list ceftazidime injection in 2 g and 6 g strengths, so the medicine remains available from other sources.

Reporting: Hospira, Inc., a Pfizer Company

Teva is permanently stopping production of palonosetron hydrochloride injection. Other makers — including Sandoz, NorthStar Rx, Sagent, and Baxter — still list this medicine as available.

Reporting: Teva Pharmaceuticals USA, Inc.

Novo Nordisk is stopping its somatropin injection 30 mg/3 mL, and this change may be permanent. Other somatropin products, including Norditropin (somatropin) in several strengths, are still listed as available from makers that have not reported a shortage.

Reporting: Novo Nordisk, Inc.

Pfizer (Hospira) is permanently stopping production of the NovaPlus vancomycin hydrochloride 10 g injection vial. Other strengths of vancomycin hydrochloride injection are still listed as available from other manufacturers.

Reporting: Hospira, Inc., a Pfizer Company

Teva is permanently stopping production of Simlandi (adalimumab-ryvk) kits. The same medicine is still listed by other makers who have not reported a shortage.

Reporting: Teva Pharmaceuticals USA, Inc.

Teva is permanently stopping production of its cetrorelix acetate injection. Other makers — including the brand Cetrotide (cetrorelix acetate) — still list supply, so the medicine remains available from those sources.

Reporting: Teva Pharmaceuticals USA, Inc.

Actavis Pharma is permanently stopping its guanfacine extended-release tablets. All four strengths (1 mg, 2 mg, 3 mg, and 4 mg) are still listed as available from other manufacturers, including Northstar RxLLC, Upsher-Smith Laboratories, and Unichem Pharmaceuticals.

Reporting: Actavis Pharma, Inc.

Endo Pharmaceuticals is permanently stopping Frova (frovatriptan) tablets. The 2.5 mg tablet is still listed as available from other manufacturers who have not reported a shortage.

Reporting: Endo Pharmaceuticals, Inc.

Hospira (a Pfizer company) is stopping production of Calcium Chloride Injection 100 mg/mL, and this change may be permanent. No other manufacturers are currently listed as a source for this medicine.

Reporting: Hospira, Inc., a Pfizer Company

Chiesi USA is stopping production of Ferriprox (deferiprone) tablets, and this change may be permanent. Other makers — including Hikma, Sun Pharmaceutical, and Dr. Reddy's — still list deferiprone tablets in 500 mg and 1000 mg strengths.

Reporting: Chiesi USA, Inc.

Pfizer (Hospira) is permanently stopping its epinephrine injection 0.1 mg/mL. The same strength is still listed as available from other manufacturers.

Reporting: Hospira, Inc., a Pfizer Company

Pfizer is permanently stopping its Novaplus-branded ketamine hydrochloride injection (500 mg/5 mL vials). The same medicine at both 50 mg/mL and 100 mg/mL strengths is still listed as available from other manufacturers.

Reporting: Pfizer Inc.

Three makers — Endo Pharmaceuticals, Teva, and Mylan — are permanently stopping everolimus tablets. Other manufacturers not reporting a shortage still list everolimus tablets in 2.5 mg, 5 mg, 7.5 mg, and 10 mg strengths.

Reporting: Endo Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., a Viatris Company, Teva Pharmaceuticals USA, Inc.

Endo Pharmaceuticals is permanently stopping production of Percocet (oxycodone/acetaminophen) tablets. The same medicine in multiple strengths is still listed by other manufacturers, including SpecGx, Major Pharmaceuticals, KVK-Tech, and Aurolife Pharma.

Reporting: Endo Pharmaceuticals, Inc.

Bristol Myers Squibb is stopping Evotaz (atazanavir/cobicistat) tablets, and this change is expected to be permanent. No other maker of this medicine has been found, so it may not be available from any source after the discontinuation takes effect.

Reporting: Bristol Myers Squibb Co.

Eli Lilly is stopping production of Reyvow (lasmiditan) tablets 50 mg and 100 mg, and distribution will end May 31, 2026. No other manufacturers make this medicine, so both strengths will have no listed source after that date.

Reporting: Eli Lilly and Co.

Padagis is permanently stopping its scopolamine transdermal patch, which may remove one source of this medicine. The 1 mg patch (including Transderm Scop) is still listed as available from other manufacturers not reporting a shortage.

Reporting: Padagis US LLC

Endo Pharmaceuticals is stopping production of phenobarbital tablets, and the change may be permanent. Other makers — including Hikma, Major Pharmaceuticals, e5 Pharma, and Trigen — still list phenobarbital tablets in 15 mg, 30 mg, 60 mg, and 100 mg strengths.

Reporting: Endo Pharmaceuticals, Inc.

Fresenius Kabi is stopping production of moxifloxacin injection 400 mg/250 mL, and this change may be permanent. The same strength is still listed by Fresenius Kabi outside the shortage report, but no manufacturer currently shows an available supply.

Reporting: Fresenius Kabi USA, LLC

AstraZeneca is stopping production of Symlin (pramlintide acetate) injection, and this change may be permanent. No other manufacturers are listed as a source for this medicine right now.

Reporting: AstraZeneca AB

Eli Lilly is discontinuing Humalog (insulin lispro) injection, and this change may be permanent, with distribution expected to end June 2027. Admelog, another insulin lispro 100 U/mL injection, is still listed by other manufacturers as available.

Reporting: Eli Lilly and Co.

Viatris is permanently stopping its busulfan injection. The 6 mg/mL injection is still listed as available from other manufacturers that have not reported a shortage.

Reporting: Mylan Institutional, a Viatris Company

Eli Lilly is stopping Basaglar (insulin glargine) injection, and this change may be permanent. Other insulin glargine products — including Lantus and Toujeo — are still listed as available from manufacturers that have not reported a shortage.

Reporting: Eli Lilly and Co.

Eli Lilly is permanently discontinuing Lyumjev (insulin lispro-aabc) injection. No other manufacturer makes this medicine, so it will not be available from any source once supplies run out.

Reporting: Eli Lilly and Co.

Teva is stopping its tranylcypromine sulfate 10 mg tablets, with supplies expected to run out by the end of 2025. Other makers — including the brand Parnate — still list this medicine as available.

Reporting: Teva Pharmaceuticals USA, Inc.

Three manufacturers — Sandoz, Sagent Pharmaceuticals, and Fresenius Kabi — are permanently stopping production of oxaliplatin injection. The 5 mg/mL strength is still listed by other makers, including Accord Healthcare, Baxter Healthcare, Eugia US, and Apotex.

Reporting: Fresenius Kabi USA, LLC, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Sandoz Inc.

Merck Sharp & Dohme is stopping Zepatier (elbasvir/grazoprevir) tablets, and the change is permanent as of December 1, 2025. No other manufacturer makes this medicine, so it will not be available from any source after that date.

Reporting: Merck Sharp & Dohme LLC

Pyros Pharmaceuticals is stopping production of vigabatrin oral solution, and this change may be permanent. Other makers have not reported a shortage and still list vigabatrin oral solution (powder for solution) at the same strength.

Reporting: Pyros Pharmaceuticals, Inc.

Pfizer is permanently stopping production of voriconazole injection (10 mg/mL). The same medicine — including Vfend (voriconazole) injection — is still listed as available from other manufacturers.

Reporting: Pfizer Inc.

Eli Lilly and Sandoz are permanently stopping all forms of Alimta (pemetrexed disodium) injection. Generic pemetrexed in multiple strengths is still listed as available from other manufacturers, including Hospira, Accord Healthcare, Sagent Pharmaceuticals, and Solco Healthcare.

Reporting: Eli Lilly and Co., Sandoz Inc.

Pfizer is stopping production of Abrilada (adalimumab-afzb) injection, and this change may be permanent. No other manufacturer of this same medicine has supply listed at this time.

Reporting: Pfizer Inc.

Sandoz is permanently stopping its omeprazole delayed-release capsules. Other makers — including Major Pharmaceuticals and NorthStar Rx — still list 10 mg, 20 mg, and 40 mg omeprazole capsules as available.

Reporting: Sandoz Inc.

Tybost (cobicistat) tablets are being discontinued by Gilead Sciences for business reasons, and the change is permanent. No other manufacturer makes this medicine, so it will not be available once current supplies sell through at the end of February 2026.

Reporting: Gilead Sciences, Inc.

AbbVie is permanently stopping production of Zemplar (paricalcitol) capsules. Generic paricalcitol capsules in 1 mcg and 2 mcg strengths are still listed as available from other manufacturers who have not reported a shortage.

Reporting: AbbVie Inc.

Meperidine hydrochloride injection has been on the FDA shortage list for over a year, though all strengths — 25 mg/mL, 50 mg/mL, and 100 mg/mL — still have available sources. Demerol (meperidine hydrochloride) 75 mg/mL injection is also listed by Hospira, which has not reported a shortage.

Reporting: Hikma Pharmaceuticals USA, Inc., Hospira, Inc., a Pfizer Company

Bacitracin ophthalmic ointment is being discontinued by Padagis, and this change may be permanent. No other manufacturer is currently listed as a source for this product.

Why: Discontinuation of the manufacture of the drug

Reporting: Padagis US LLC

Methylphenidate extended-release film tablets are listed as in shortage, though all strengths (10 mg, 15 mg, 20 mg, and 30 mg) still have at least one available source. Methylphenidate patches are listed by makers not reporting a shortage.

Reporting: Noven Pharmaceuticals, Inc.

Generic hydroxocobalamin injection is unavailable from the one maker reporting a shortage, while Cyanokit (hydroxocobalamin) 5 g/250 mL injection remains available to order. The 30 mL multi-dose vial currently has no listed source from any reporting manufacturer.

Why: Other

Reporting: BTG International Inc., Teva Pharmaceuticals USA, Inc.

Dextrose Monohydrate 70% Injection has been in shortage for over a year, though all three manufacturers reporting the shortage still list some supply available. The 70 g/100 mL strength remains sourced, but Baxter Healthcare does not expect full recovery until September 2026.

Why: Other

Reporting: B. Braun Medical Inc., Baxter Healthcare, Otsuka ICU Medical LLC

Tiglutik / Teglutik (riluzole) oral suspension has been in shortage for over a year due to manufacturing compliance issues. The 5 mg/1 mL strength still has supply from the one reporting manufacturer, but the 50 mg/10 mL strength currently has no listed source.

Why: Requirements related to complying with good manufacturing practices

Reporting: EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)

Technetium Tc-99m pyrophosphate kit injection is in shortage, mainly due to an active ingredient supply problem that has lasted over a year. The 12 mg/10 mL strength has no available source right now; the 11.9 mg and 3.2 mg strengths remain on allocation from one of the two manufacturers.

Why: Other; Shortage of an active ingredient

Reporting: Curium US LLC, Sun Pharmaceutical Industries, Inc.

Promethazine hydrochloride injection has been on the FDA shortage list for over a year due to increased demand. Both available strengths (25 mg/mL and 50 mg/mL) still have listed supply from reporting manufacturers, though availability is limited and fuller recovery is not expected until around October 2026.

Why: Demand increase for the drug; Other

Reporting: Hikma Pharmaceuticals USA, Inc., XGen Pharmaceuticals DJB, Inc.

Generic cromolyn sodium concentrate is in short supply, with some versions limited — but Gastrocrom (the brand) remains available, and all reporting manufacturers still list at least some supply of the 20 mg/mL and 100 mg/5 mL strengths.

Why: Other

Reporting: Ailex Pharmaceuticals, Micro Labs LTD, Mylan Specialty, a Viatris Company, Rising Pharma Holdings, Inc.

Propranolol injection is in shortage due to a lack of active ingredient, and has been for over a year. One of two makers still lists supply available — check wholesalers for current stock.

Why: Shortage of an active ingredient

Reporting: Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA, Inc.

Methylphenidate extended-release tablets have been in shortage for over a year. Most strengths still have at least one supplier, and some makers not reporting a shortage list this medicine.

Why: Demand increase for the drug; Other; Discontinuation of the manufacture of the drug

Reporting: Janssen Pharmaceuticals, Lannett Company, Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceuticals USA, Inc. and 2 more

Victoza and Saxenda (liraglutide) injections are in short supply, with some versions being discontinued, though Victoza's supply remains mostly available and the 6 mg/mL strength is still listed by several other manufacturers not reporting a shortage.

Why: Delay in shipping of the drug; Discontinuation of the manufacture of the drug

Reporting: Hikma Pharmaceuticals USA, Inc., Meitheal Pharmaceuticals, Inc., Novo Nordisk, Inc., Teva Pharmaceuticals USA, Inc.

Generic Vyvanse (lisdexamfetamine) capsules are in shortage, with about 40% of generic products unavailable or limited — though Vyvanse brand capsules themselves are fully available. Generic versions at all strengths are still listed by some manufacturers not reporting a shortage, including Sandoz, Camber Pharmaceuticals, AvKARE, and American Health Packaging.

Why: Shortage of an active ingredient; Other; Delay in shipping of the drug

Reporting: Alvogen, Amneal Pharmaceuticals, Apotex Corp., Elite Laboratories, Inc. and 9 more

Vyvanse (lisdexamfetamine) chewable tablets are on the FDA shortage list, but the brand-name Vyvanse chewable tablets show all products available — the shortage is mainly among generic versions. Generic lisdexamfetamine chewable tablets are still listed by makers not reporting a shortage, including SpecGx, Teva, Camber, and Granules Pharmaceuticals.

Reporting: Novadoz Pharmaceuticals LLC, Sun Pharmaceutical Industries, Inc., Takeda Pharmaceuticals USA Inc.

Carboplatin injection is in a nationwide shortage that has lasted over a year, with several vial sizes currently having no available source. Some strengths remain available from makers not reporting a shortage, including 450 mg/45 mL and 600 mg/60 mL sizes.

Why: Other; Discontinuation of the manufacture of the drug; Demand increase for the drug

Reporting: Accord Healthcare Inc., Avyxa Pharma, LLC, Eugia US LLC, Fresenius Kabi USA, LLC and 5 more

Sterile Water Irrigant is currently in shortage, driven by manufacturing discontinuations and rising demand. Most strengths still have supply from other makers, including B. Braun Medical and ICU Medical.

Why: Discontinuation of the manufacture of the drug; Other

Reporting: B. Braun Medical Inc., Baxter Healthcare, Otsuka ICU Medical LLC

Pfizer is permanently stopping production of prazosin hydrochloride capsules. Other makers — including Teva, Mylan, Major Pharmaceuticals, and Marlex — still list prazosin capsules in 1 mg, 2 mg, and 5 mg strengths, so the medicine may be available through other sources.

Reporting: Pfizer Inc.

Bicillin L-A (penicillin G benzathine) injection has been in shortage for over a year due to manufacturing delays. Most strengths still have some supply from reporting makers, though the 600,000 IU/mL strength has no listed source from any manufacturer right now.

Why: Other

Reporting: Laboratorios Atral, Pfizer Inc.

Pfizer is stopping production of Cleocin Phosphate (clindamycin phosphate) injection, and the generic versions from other makers are in short supply, though most reporting manufacturers still list some strengths as available. Hikma Pharmaceuticals also lists clindamycin injection products that are not part of this shortage report.

Why: Demand increase for the drug; Discontinuation of the manufacture of the drug

Reporting: Baxter Healthcare, Pfizer Inc., Sagent Pharmaceuticals, Sandoz Inc.

Methotrexate sodium injection has been in shortage for over a year, driven by rising demand. Some strengths remain available from several manufacturers, and no strengths are currently listed without any supply source.

Why: Other; Demand increase for the drug

Reporting: Accord Healthcare Inc., Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA, Inc., Hospira, Inc., a Pfizer Company and 1 more

Generic clonazepam tablets are in limited supply from some manufacturers, though all three Klonopin (clonazepam) brand products remain available. Generic versions are still listed by makers not reporting a shortage, including Major Pharmaceuticals and others, across all strengths (0.5 mg, 1 mg, 2 mg).

Why: Other

Reporting: Accord Healthcare Inc., Aurobindo Pharma USA, Cheplapharm Arzneimittel GmbH, Prinston Pharmaceutical, Inc. and 2 more

Rocuronium bromide injection has been in shortage for over a year due to shipping delays and rising demand. All strengths still have listed supply from reporting manufacturers, and additional makers not reporting a shortage also list this medicine as available.

Why: Delay in shipping of the drug; Demand increase for the drug

Reporting: Baxter Healthcare, Eugia US LLC, Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA, Inc. and 7 more

Quinapril hydrochloride tablets are in a shortage that has lasted over a year, with most manufacturers either discontinuing the drug or facing long-term backlogs with no clear restock date. Some makers not reporting a shortage — including Proficient Rx LP, BluePoint Laboratories, and Cipla USA — still list supply at multiple strengths.

Why: Discontinuation of the manufacture of the drug; Requirements related to complying with good manufacturing practices; Shortage of an active ingredient

Reporting: Aurobindo Pharma USA, Chartwell Molecular Holdings LLC, Lupin Pharmaceuticals, Inc., Solco Healthcare US, LLC

Aurobindo Pharma USA is stopping its quinapril/hydrochlorothiazide tablets, and this change may be permanent. The same medicine is still listed by other manufacturers, including Lupin Pharmaceuticals and Cipla USA, so supply exists from sources not reporting a shortage.

Why: Discontinuation of the manufacture of the drug

Reporting: Aurobindo Pharma USA, Chartwell Molecular Holdings LLC

Mixed amphetamine salts tablets (the generic form of Adderall) have been in shortage for over a year, driven by ingredient supply problems and rising demand. Some manufacturers are not reporting a shortage, so certain strengths may still be available depending on the pharmacy's supplier.

Why: Shortage of an active ingredient; Demand increase for the drug; Other

Reporting: Alvogen, Aurobindo Pharma USA, Elite Laboratories, Inc., Epic Pharma, LLC and 7 more

Most versions of Amidate (etomidate) injection are still available, but this shortage — ongoing for over a year — is mostly affecting generic products, with 2 of 16 generic versions unavailable; the Amidate brand itself has 1 of 2 products available. The 2 mg/mL and 2 mg/1 mL strengths still have listed sources, though the 20 mg/10 mL and 40 mg/20 mL sizes currently have none.

Why: Demand increase for the drug; Other

Reporting: Caplin Steriles, Ltd., Eugia US LLC, Gland Pharma Limited, Hikma Pharmaceuticals USA, Inc. and 2 more

Flurazepam hydrochloride capsules are in shortage due to a manufacturing delay, with one of two reporting makers still listing supply in both the 15 mg and 30 mg strengths. Rising Pharma does not expect its supply to return until late 2026, so availability may be limited depending on which manufacturer your pharmacy sources from.

Why: Regulatory delay

Reporting: Chartwell Molecular Holdings LLC, Rising Pharma Holdings, Inc.

Streptozocin powder for solution is currently in shortage, with the 100 mg/1 mL concentration having no available source right now. The 1 g/10 mL strength still has a listed supply from one manufacturer.

Why: Other

Reporting: ESTEVE PHARMACEUTICALS, S.A., Teva Pharmaceuticals USA, Inc.

The shortage of Ultiva (remifentanil) is mostly in the generic versions — specifically the 1 mg per vial and 2 mg per vial strengths, which currently have no listed source. All three Ultiva brand products remain available, though this shortage has lasted over a year.

Why: Demand increase for the drug; Delay in shipping of the drug

Reporting: Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA, Inc., Mylan Institutional, a Viatris Company

Sufentanil citrate injection is in shortage, and Hikma is not currently making it. One of the two manufacturers still lists some supply, but not all strengths are available, and no other makers are on record as an alternative source.

Why: Other

Reporting: Hikma Pharmaceuticals USA, Inc., Hospira, Inc., a Pfizer Company

Vaprisol Dextrose In Plastic Container (conivaptan hydrochloride) injection 20 mg/100 mL has been in shortage for over a year due to shipping delays, with no recovery date set. No other makers of this medicine are currently listed as an alternative source.

Why: Delay in shipping of the drug

Reporting: Cumberland Pharmaceuticals Inc.

Dextrose Monohydrate 10% Injection has been on the shortage list for over a year, with at least one maker stopping production. All four reporting manufacturers still list some supply available, and Becton Dickinson also lists the 100 mg/mL strength without reporting a shortage.

Why: Discontinuation of the manufacture of the drug

Reporting: B. Braun Medical Inc., Baxter Healthcare, Fresenius Kabi USA, LLC, Otsuka ICU Medical LLC